Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11624MR)

This product GTTS-WQ11624MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Mus musculus; Humanized
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11624MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5128MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ898MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ2811MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ7784MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ6549MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ1401MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ2387MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ8848MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW